View in EDS

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial.

Saved in:
Bibliographic Details
Title: Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial.
Authors: Roth, Eli M.1 eroth@sterlingresearch.org, Taskinen, Marja-Riitta2, Ginsberg, Henry N.3, Kastelein, John J. P.4, Colhoun, Helen M.5, Robinson, Jennifer G.6, Merlet, Laurence7, Pordy, Robert8, Baccara-Dinet, Marie T.9
Source: International Journal of Cardiology. Sep2014, Vol. 176 Issue 1, p55-61. 7p.
Database: Academic Search Ultimate
Description
ISSN:01675273
DOI:10.1016/j.ijcard.2014.06.049